ABAX --- lots of upside Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ABAX --- lots of upside

ABAX 83.00

0.0%

Aug 1 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Yo Yo who wrote (402)	4/1/1998 1:12:00 PM
From: burner	Read Replies (2) of 492

Did you receive a mailing from Coffin Communications? I received a two-part mailing one with a profile of the company and information on investment opportunity. It mentions the company being significantly undervalued with strong top-line growth and bottom-line improvement. Indeed, the accompanying graphs for Quarterly Revenue; Gross Margin; and Quarterly Disc Units do show obvious sustained improvement. The other part compares Abaxis with other companies in its peer group; Biocircuits, Cholestech, Diametrics, Idexx, and I-Stat. Mention is made of only one company (Cholestec) being currently profitable and the rest having greater losses on a trailing 12 month basis. "yet they all trade at much greater multiples of their trailing twelve month sales than ABAXIS". For the record ABAX leads in 5 yr Sales Growth at 123.90% The information sheet concludes: " with added menus, ABAXIS believes it can compete for at least 20% of the entire $5 billion clinical chemistry market". It also states that even without additions to menu a lot of room is left for increasing sales from the current $11.4 million to a possible $300 million market. The writer of the report is John Muir (818) 789-0100 Dan

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next